Feraheme, Rienso(ferumoxytol)
Feraheme, Ferumoxytol, Rienso (ferumoxytol) is an unknown pharmaceutical. Ferumoxytol was first approved as Feraheme on 2009-06-30. It is used to treat iron-deficiency anemia in the USA. It has been approved in Europe to treat anemia and chronic kidney failure.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Feraheme, Ferumoxytol
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ferumoxytol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FERAHEME | Covis Pharma | N-022180 RX | 2009-06-30 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| feraheme | New Drug Application | 2022-06-13 |
| ferumoxytol | ANDA | 2022-06-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| iron-deficiency anemia | HP_0001891 | D018798 | D50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
Clinical
No data
Drug
General
| Drug common name | Ferumoxytol |
| INN | — |
| Description | Iron(II,III) oxide, or black iron oxide, is the chemical compound with formula Fe3O4. It occurs in nature as the mineral magnetite. It is one of a number of iron oxides, the others being iron(II) oxide (FeO), which is rare, and iron(III) oxide (Fe2O3) which also occurs naturally as the mineral hematite. It contains both Fe2+ and Fe3+ ions and is sometimes formulated as FeO ∙ Fe2O3. This iron oxide is encountered in the laboratory as a black powder. It exhibits permanent magnetism and is ferrimagnetic, but is sometimes incorrectly described as ferromagnetic. Its most extensive use is as a black pigment (see: Mars Black). For this purpose, it is synthesized rather than being extracted from the naturally occurring mineral as the particle size and shape can be varied by the method of production.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1309-38-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201867 |
| ChEBI ID | — |
| PubChem CID | 16211978 |
| DrugBank | DB06215 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Feraheme – AMAG Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
No data
Safety
Black-box Warning
Black-box warning for: Feraheme, Ferumoxytol
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use